We are monitoring the impact of COVID-19 on Liquid Biopsy Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 889
Share on
Share on

Global Liquid Biopsy Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Cancer Type, Sample Type, Diagnostic Approach, End Users and Region - Industry Forecast (2021 to 2026)

Pulished: February, 2020
ID: 889
Pages: 175

Global Liquid Biopsy Market Size, Growth (2021 to 2026)

As per our analysis report, the global liquid biopsy market size is estimated to grow at a CAGR of 24.3% from 2021 to 2026. As per our report, this market is estimated at USD 1449.3 Million in 2021 and is predicted to grow USD 4300.5 million by 2026. During the forecast period, the North American regional market is forecasted to account for most of the liquid biopsy market share in the global market.

Liquid biopsy is a minimally invasive medical procedure done by collecting blood samples to diagnose the cancer cells from a tumor circulating in the blood. A tumor releases various biomolecules into the bloodstream examined via a blood test. The biopsy process is to identify cancer at an early stage. The biopsy surgeries were found to be highly accurate. The procedure requires 5milliliters of blood which is easier to makes the process very easy and quick. The liquid biopsy procedure is less invasive when compared with the tissue biopsy process. The course can be easily repeated if needed and used often to monitor the patient's health condition. The procedure is less costly when compared with that of tissue biopsy. The Food and Drug Administration (FDA) has approved the liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers. For instance, in Canada, cancer is the leading cause of death among the population. It is witnessed to be the second leading cause of heart diseases in the U.S. As per the American Cancer Society, Inc., around 1.9 million new cancer cases and 693,000 cancer deaths were recorded in 2018. 

MARKET DRIVERS:

Increasing demand for personalized medicine, the growing prevalence of a non-invasive minimal surgical procedure, and the rising number of healthcare centers are the major drivers propelling the global liquid biopsy market growth.

Liquid biopsy enhances the performance of an application with its services. Ongoing research and developments in biotechnology to launch various products, the rise in the incidences of multiple health disorders, and increasing cancer diseases worldwide escalate the market demand. A growing population is leveraging the growth of the global liquid biopsy market.

Furthermore, increasing demand for early diagnosis of the diseases as there is a permanent cure at the first stage of the diseases, the emergence of the latest technological developments in the medical sector, growing focus on developing innovative kinds of techniques for diagnosing and treating varied diseases are further magnifying the global liquid biopsy market. The rise in the concern towards health, increasing awareness in doctors to make the best decisions in treating the diseases with an appropriate plan to promote the wellbeing of the patient is boosting up the demand of the market. Furthermore, liquid biopsy helps ensure effective treatment procedures for the physicians, which is expected to favor the market growth in the coming years.

MARKET RESTRAINTS:

Lack of skilled persons in handling the systems, the cost for installation of the devices is a bit expensive are the key challenging factors to the global liquid biopsy market.

Increasing complications in real-time due to sudden failures of the systems and maintenance of the devices also need massive amounts, which are a burden for the small-scale industries are further limiting the growth of the Global Liquid Biopsy Market.

Impact of COVID-19 on the global liquid biopsy market:

The COVID-19 pandemic has affected all aspects of life worldwide and impacted all businesses, including medical healthcare. The pandemic management has darkened the cancer prevention surging delay in diagnosis and focusing on significant survival reduction. Liquid biopsy decreases the risk of COVID-19 disease during the procedures. Patients who have cancer are at high risk for critical events and are associated with low-quality results after COVID-19 infection than singles without cancer. Delays in surgery for incidental cancers significantly affect the long-term survival of patients with cancer. However, the market shares are expected to grow at a higher rate in 2021.  

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Cancer Type, Diagnostic Approach, Sample Type, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global liquid biopsy market has been segmented and sub-segmented based on cancer type, diagnostic approach, sample type, end-user, and region.

Liquid Biopsy Market Analysis - By Cancer Type:

  • Lung Cancer
  • Pancreatic Cancer
  • Leukemia
  • Visceral Cancers

Based on cancer type, the lung cancer segment is holding prominent shares of the market. The rise in awareness among people over the availability of different treatment procedures for various types of cancer is prompting the growth of the liquid biopsy market. The growing prevalence of useful diagnostic and treatment procedures is influencing the growth of the market eventually. The increasing geriatric population is one of the factors propelling the growth of the market.

Liquid Biopsy Market Analysis - By Diagnostic approach:

  • Circulating Tumour cells (CTC)
  • Circulating Tumour DNA (ctDNA test)
  • RNA in exosomes
  • Extra-Cellular Vesicles

More than 8-10 CTCs and ctDNA tests are currently commercialized. 

CTCs (Circulating Tumour cells), the first such entities on the liquid biopsy scene, have accounted for a significant market share. Cancer institute is the largest end-user segment in terms of revenues and is expected to create substantial opportunities in the global liquid biopsy market over the forecast period.    

Liquid Biopsy Market Analysis - By Sample Type:

  • Blood
  • Urine
  • Plasma
  • Saliva
  • Cerebrospinal Fluid

Based on the sample type, the blood sample type has the fastest growth rate from the past few years and is anticipated to have a significant growth rate in the coming years. The growing number of diagnostic centers worldwide with the latest equipment is escalating the demand for this market. Also, people's interest in early diagnosis of the disease where there is a permanent cure for the diseases when it is treated at first levels shows a positive impact on the growth of the market.

Liquid Biopsy Market – By End User:

  • Reference Laboratories
  • Hospital/Physician Laboratories
  • Academic and Research Centres

Based on End-User, the laboratories segment is dominating with the most significant shares of the market. Focus on improving the patient's health condition by evaluating quality treatment procedures is broadening the demand of this market.

Liquid Biopsy Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

The North American market is geographically witnessed in holding the highest shares of the global liquid biopsy market. Increasing capital income in both developed and developing countries is fueling the demand of the market. Additionally, the rising chronic diseases such as cancer and other diseases are accelerating the market's need. Also, the growing focus on the launch of new techniques for diagnosis is leveling up the growth of the market extensively.

The Asia Pacific is positioned second in holding dominant shares of the global liquid biopsy market. The rise in the geriatric population is spurring the growth rate of the market. Along with this, increasing support from private and public organizations is gearing up the market demand. India and China are the major countries in the Asia Pacific, contributing their highest shares for the market.

Europe is accounted for in having the fastest growth rate from the past decade and is also expected to grow in the coming years significantly. The rise in the demand to improve the quality of the treatment is expanding the market shares. Increasing focus on lowering the cost of treatment and diagnostics applications in the medical sector magnifies the market demand. Increasing training institutes in the pharmaceutical industry are also showing potential growth rates for the market.

The Middle East and Africa are anticipated to have a significant growth rate during the forecast period. The rise in government support by launching reimbursement schemes is surging the demand of the liquid biopsy market.

KEY PARTICIPANTS IN THIS MARKET:

Companies leading the global liquid biopsy market profiled in the report are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex InosticsTrovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.

RECENT HAPPENINGS IN THIS MARKET:

  • In March 2017, Adha Test Prostate Cancer Panel AR-V7 was introduced by QIAGEN N.V. (Netherlands). It is used to detect the androgen receptor splice variant seven and promote better treatment for the patient.
  • In March 2017, AVENIO circulating tumor DNA (ctDNA) Analysis Kits was introduced by Roche Diagnostics, where it plays an essential role in all Next Generation Sequencing (NGS) laboratories.
  • In April 2017, the partnership between Myriad Genetics Inc. (U.S.) and BeiGene (Cayman Islands) had strengthened the position of the companies in the market. The main focus of BioGene, a biopharmaceutical company, is to develop molecularly targeted and immune-oncology drug candidates for cancer patients. These drugs are very effective in treating cancer and promoting healthcare services in hospitals. Also, this partnership has brought many changes in the laboratories as they are using Myriad's myChoice HRD and BRACAnalysis CDx companion diagnostic tests.
  • In April 2017, Janssen Diagostics LLC. (the U.S.) is acquired by Menarini Silicon Biosystems (Italy), and this is related to the CELL SEARCH Circulating Tumor Cell System. With this acquisition, Menarini Silicon Biosystems (Italy) has made its first entry into the U.S. diagnostics market.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Cancer Type                                         

                                5.1.1 Lung Cancer                           

                                5.1.2 Pancreatic Cancer                

                                5.1.3 Leukemia                

                                5.1.4 Other Visceral Cancers                       

                5.2 By Sample Type                                        

                                5.2.1 Blood                        

                                5.2.2 Urine                         

                                5.2.3 Plasma                      

                                5.2.4 Saliva                         

                                5.2.5 Cerebrospinal                        

                5.3 By Diagnostic Approach                                        

                                5.3.1 Circulating Tumour cells (CTC)                        

                                5.3.2 Circulating Tumour DNA (ctDNA test)                  

                                5.3.3 RNA in exosomes                 

                                5.3.4 Extra-Cellular Vesicles                        

                5.4 By End Users                                             

                                5.4.1 Reference Laboratories                     

                                5.4.2 Hospital/Physician Laboratories                     

                                5.4.3 Academic and Research Centers                    

                                5.4.4 Other End Users                   

6. Geographical Analysis                                                              

                6.1 North America                                          

                                6.1.1 Introduction                           

                                6.1.2 United States                         

                                6.1.3 Canada                     

                6.2 Europe                                         

                                6.2.1 Introduction                           

                                6.2.2 U.K                             

                                6.2.3 Spain                         

                                6.2.4 Germany                 

                                6.2.5 Italy                           

                                6.2.6 France                      

                6.3 Asia-Pacific                                 

                                6.3.1 Introduction                           

                                6.3.2 China                         

                                6.3.3 India                          

                                6.3.4 Japan                        

                                6.3.5 South Korea                           

                                6.3.6 Australia                  

                6.4 Latin America                                            

                                6.4.1 Introduction                           

                                6.4.2 Brazil                         

                                6.4.3 Mexico                     

                                6.4.4 Argentina                

                                6.4.5 Rest of Latin America                         

                6.5 Middle East & Africa                               

                                6.5.1 Introduction                           

                                6.5.2 Middle-East                            

                                6.5.3 Africa                        

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                      

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services               

                                7.2.5 Competitive Rivalry within the Industry                      

8. Market Leaders' Analysis                                                        

                8.1 Janssen Diagnostics                                

                                8.1.1 Overview                

                                8.1.2 Product Analysis                   

                                8.1.3 Strategic Evaluation and Operations                            

                                8.1.4 Financial analysis                  

                                8.1.5 Legal issues                            

                                8.1.6 Recent Developments                       

                                8.1.7 SWOT analysis                       

                                8.1.8 Analyst View                          

                8.2 Qiagen                                         

                8.3 Rarecells SAS                                             

                8.4 Silicon Biosystems                                   

                8.5 SRI International                                      

                8.6 Myriad Genetics                                      

                8.7 Natera                                          

                8.8 Personal Genome Diagnostics                                            

                8.9 Sysmex Inostics                                        

                8.10 Trovagene                                

                8.11 Exosome Diagnostics                                           

                8.12 HansaBiomed OU                                  

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                        

                9.3 Agreements, collaborations and Joint Ventures                                          

                9.4 New Product Launches                                          

10. Expert Opinions                                                        

                10.1 Market Outlook                                     

                10.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  3. Global Lung Cancer Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  8. Global Blood Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Urine Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Plasma Market, By Region, From 2021 to 2026 (USD Million)
  11. Global Saliva Market, By Region, From 2021 to 2026 (USD Million)
  12. Global Cerebrospinal Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  14. Global Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Million)
  15. Global Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Million)
  16. Global RNA in exosomes Market, By Region, From 2021 to 2026 (USD Million)
  17. Global Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Million)
  18. Global Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  19. Global Reference Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  20. Global Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  21. Global Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Million)
  22. Global Other End Users Market, By Region, From 2021 to 2026 (USD Million)
  23. North America Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  25. North America Lung Cancer Market, By Region, From 2021 to 2026 (USD Million)
  26. North America Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Million)
  27. North America Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  28. North America Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Million)
  29. North America Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  30. North America Blood Market, By Region, From 2021 to 2026 (USD Million)
  31. North America Urine Market, By Region, From 2021 to 2026 (USD Million)
  32. North America Plasma Market, By Region, From 2021 to 2026 (USD Million)
  33. North America Saliva Market, By Region, From 2021 to 2026 (USD Million)
  34. North America Cerebrospinal Market, By Region, From 2021 to 2026 (USD Million)
  35. North America Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  36. North America Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Million)
  37. North America Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Million)
  38. North America RNA in exosomes Market, By Region, From 2021 to 2026 (USD Million)
  39. North America Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Million)
  40. North America Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  41. North America Reference Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  42. North America Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  43. North America Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Million)
  44. North America Other End Users Market, By Region, From 2021 to 2026 (USD Million)
  45. United States Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  46. United States Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  47. United States Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  48. United States Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  49. Canada Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  50. Canada Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  51. Canada Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  52. Canada Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  53. Europe Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Million)
  54. Europe Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  55. Europe Lung Cancer Market, By Region, From 2021 to 2026 (USD Million)
  56. Europe Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Million)
  57. Europe Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  58. Europe Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Million)
  59. Europe Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  60. Europe Blood Market, By Region, From 2021 to 2026 (USD Million)
  61. Europe Urine Market, By Region, From 2021 to 2026 (USD Million)
  62. Europe Plasma Market, By Region, From 2021 to 2026 (USD Million)
  63. Europe Saliva Market, By Region, From 2021 to 2026 (USD Million)
  64. Europe Cerebrospinal Market, By Region, From 2021 to 2026 (USD Million)
  65. Europe Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  66. Europe Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Million)
  67. Europe Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Million)
  68. Europe RNA in exosomes Market, By Region, From 2021 to 2026 (USD Million)
  69. Europe Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Million)
  70. Europe Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  71. Europe Reference Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  72. Europe Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  73. Europe Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Million)
  74. Europe Other End Users Market, By Region, From 2021 to 2026 (USD Million)
  75. U.K Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  76. U.K Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  77. U.K Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  78. U.K Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  79. Spain Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  80. Spain Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  81. Spain Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  82. Spain Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  83. Germany Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  84. Germany Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  85. Germany Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  86. Germany Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  87. Italy Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  88. Italy Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  89. Italy Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  90. Italy Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  91. France Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  92. France Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  93. France Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  94. France Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  95. Asia-Pacific Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Million)
  96. Asia-Pacific Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  97. Asia-Pacific Lung Cancer Market, By Region, From 2021 to 2026 (USD Million)
  98. Asia-Pacific Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Million)
  99. Asia-Pacific Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  100. Asia-Pacific Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Million)
  101. Asia-Pacific Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  102. Asia-Pacific Blood Market, By Region, From 2021 to 2026 (USD Million)
  103. Asia-Pacific Urine Market, By Region, From 2021 to 2026 (USD Million)
  104. Asia-Pacific Plasma Market, By Region, From 2021 to 2026 (USD Million)
  105. Asia-Pacific Saliva Market, By Region, From 2021 to 2026 (USD Million)
  106. Asia-Pacific Cerebrospinal Market, By Region, From 2021 to 2026 (USD Million)
  107. Asia-Pacific Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  108. Asia-Pacific Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Million)
  109. Asia-Pacific Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Million)
  110. Asia-Pacific RNA in exosomes Market, By Region, From 2021 to 2026 (USD Million)
  111. Asia-Pacific Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Million)
  112. Asia-Pacific Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  113. Asia-Pacific Reference Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  114. Asia-Pacific Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  115. Asia-Pacific Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Million)
  116. Asia-Pacific Other End Users Market, By Region, From 2021 to 2026 (USD Million)
  117. China Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  118. China Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  119. China Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  120. China Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  121. India Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  122. India Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  123. India Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  124. India Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  125. Japan Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  126. Japan Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  127. Japan Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  128. Japan Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  129. South Korea Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  130. South Korea Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  131. South Korea Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  132. South Korea Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  133. Australia Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  134. Australia Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  135. Australia Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  136. Australia Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  137. Latin America Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Million)
  138. Latin America Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  139. Latin America Lung Cancer Market, By Region, From 2021 to 2026 (USD Million)
  140. Latin America Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Million)
  141. Latin America Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  142. Latin America Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Million)
  143. Latin America Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  144. Latin America Blood Market, By Region, From 2021 to 2026 (USD Million)
  145. Latin America Urine Market, By Region, From 2021 to 2026 (USD Million)
  146. Latin America Plasma Market, By Region, From 2021 to 2026 (USD Million)
  147. Latin America Saliva Market, By Region, From 2021 to 2026 (USD Million)
  148. Latin America Cerebrospinal Market, By Region, From 2021 to 2026 (USD Million)
  149. Latin America Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  150. Latin America Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Million)
  151. Latin America Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Million)
  152. Latin America RNA in exosomes Market, By Region, From 2021 to 2026 (USD Million)
  153. Latin America Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Million)
  154. Latin America Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  155. Latin America Reference Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  156. Latin America Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  157. Latin America Academic and Research Centers Market, By Region, From 2021 to 2026 (USD Million)
  158. Latin America Other End Users Market, By Region, From 2021 to 2026 (USD Million)
  159. Brazil Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  160. Brazil Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  161. Brazil Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  162. Brazil Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  163. Argentina Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  164. Argentina Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  165. Argentina Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  166. Argentina Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  167. Mexico Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  168. Mexico Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  169. Mexico Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  170. Mexico Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  171. Middle East & Africa Liquid Biopsy Market, By Region, From 2021 to 2026 (USD Million)
  172. Middle East & Africa Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  173. Middle East & Africa Lung Cancer Market, By Region, From 2021 to 2026 (USD Million)
  174. Middle East & Africa Pancreatic Cancer Market, By Region, From 2021 to 2026 (USD Million)
  175. Middle East & Africa Leukemia Market, By Region, From 2021 to 2026 (USD Million)
  176. Middle East & Africa Other Visceral Cancers Market, By Region, From 2021 to 2026 (USD Million)
  177. Middle East & Africa Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  178. Middle East & Africa Blood Market, By Region, From 2021 to 2026 (USD Million)
  179. Middle East & Africa Urine Market, By Region, From 2021 to 2026 (USD Million)
  180. Middle East & Africa Plasma Market, By Region, From 2021 to 2026 (USD Million)
  181. Middle East & Africa Saliva Market, By Region, From 2021 to 2026 (USD Million)
  182. Middle East & Africa Cerebrospinal Market, By Region, From 2021 to 2026 (USD Million)
  183. Middle East & Africa Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  184. Middle East & Africa Circulating Tumour cells (CTC) Market, By Region, From 2021 to 2026 (USD Million)
  185. Middle East & Africa Circulating Tumour DNA (ctDNA) Market, By Region, From 2021 to 2026 (USD Million)
  186. Middle East & Africa RNA in exosomes Market, By Region, From 2021 to 2026 (USD Million)
  187. Middle East & Africa Extra-Cellular Vesicles Market, By Region, From 2021 to 2026 (USD Million)
  188. Middle East & Africa Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  189. Middle East & Africa Reference Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  190. Middle East & Africa Hospital/Physician Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  191. Middle East & Africa Academic and Research Centres Market, By Region, From 2021 to 2026 (USD Million)
  192. Middle East & Africa Other End Users Market, By Region, From 2021 to 2026 (USD Million)
  193. Middle East Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  194. Middle East Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  195. Middle East Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  196. Middle East Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)
  197. Africa Liquid Biopsy Market, By Cancer Type, From 2021 to 2026 (USD Million)
  198. Africa Liquid Biopsy Market, By Sample Type, From 2021 to 2026 (USD Million)
  199. Africa Liquid Biopsy Market, By Diagnostic Approach, From 2021 to 2026 (USD Million)
  200. Africa Liquid Biopsy Market, By End Users, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample